Will this biotech's innovative platform finally pay off?
Intellia Therapeutics' stock is downgraded to HOLD due to market skepticism and lack of near-term catalysts despite promising Phase 3 trials for HAE and ATTR. NTLA-2002, Intellia's CRISPR/Cas9 drug ...
Zacks Investment Research on MSN
Take the Zacks approach to beat the markets: Intellia, Colgate-Palmolive, Getty in focus
Last Friday, the three most widely followed benchmark indexes closed a winning week. The Nasdaq Composite, the S&P 500 and ...
Why Intellia Therapeutics Is Back on Watchlists Intellia Therapeutics (NTLA) has drawn renewed attention after a sharp move in its share price over the past 3 months, inviting investors to reassess ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best innovative stocks to buy according to Wall Street analysts.
The last time I wrote about Intellia Therapeutics (NTLA) it was with respect to a Seeking Alpha article entitled "Intellia Therapeutics: Lower Stock Price On HAE Data Presents A Buying Opportunity".
PHILADELPHIA, PA / ACCESS Newswire / October 29, 2025 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Intellia Therapeutics, Inc. ("Intellia" or the ...
The MarketWatch News Department was not involved in the creation of this content. CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading ...
Intellia Therapeutics NTLA has put up a stellar performance in the past month. Shares of the company have rallied 29.8% compared with the industry’s rise of 0.4%. The stock has also outperformed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results